Trials / Completed
CompletedNCT05965778
Performance and Safety of T2769 in DED
Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 251 (actual)
- Sponsor
- Laboratoires Thea · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate the non-inferiority of T2769 compared to Vismed® Multi in terms of total ocular surface staining (Oxford score) after 35 days of treatment. To evaluate the performance and safety of T2769 versus Vismed® Multi.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | T2769 | T2769: sodium hyaluronate, Trehalose, Naaga in a 12.5 mL ABAK® multi-dose bottle. |
| DEVICE | Vismed® Multi | Hyaluronic acid |
Timeline
- Start date
- 2023-10-02
- Primary completion
- 2024-08-15
- Completion
- 2024-08-15
- First posted
- 2023-07-28
- Last updated
- 2026-01-23
- Results posted
- 2026-01-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05965778. Inclusion in this directory is not an endorsement.